Drug Trial Radar · NCT07455734
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
533
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Oct 2030
Study completion Oct 2030
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- BioNTech (Shanghai) Pharmaceuticals Co., Ltd.; Biotheus (Hengqin) Co., Ltd.
- First posted
- Mar 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.
Conditions
- Advanced Solid Tumor Cancer
Interventions
BNT3214Drug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- All parts - Number and percentage of participants with treatment emergent adverse events (TEAEs)Time frame: From the time of initiation of the first dose of BNT3214 until 90 days after the last dose of BNT3214
- All parts - Number and percentage of participants with dose interruptions, reductions, and discontinuation of BNT3214 due to TEAEsTime frame: Up to 24 months
- Parts A and B only - Number and percentage of participants with dose limiting toxicities (DLTs)Time frame: From first dose up to 28 days
- Part C only - Objective response rate (ORR)Time frame: Up to 30 months
Locations
16 sites in 4 countries. Site status is shown where the registry gives one.
Monash Medical Centre Clayton
Clayton, Australia · Recruiting
Austin Health
Heidelberg Heights, Australia · Not yet recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Not yet recruiting
Scientia Clinical Research Ltd
Randwick, Australia · Not yet recruiting
Epworth HealthCare
Richmond, Australia · Recruiting
Chongqing University Cancer Hospital
Chongqing, China · Recruiting
Nanfang Hospital of Southern Medical University
Guangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Not yet recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China · Recruiting
Seoul National University Bundang Hospital
Seongnam, South Korea · Not yet recruiting
Seoul National University Hospital
Seoul, South Korea · Not yet recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Not yet recruiting
Asan Medical Center
Seoul, South Korea · Not yet recruiting
China Medical University Hospital
Taichung, Taiwan · Not yet recruiting
National Taiwan University Hospital
Taipei, Taiwan · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.